Insight into the Structural Features of Pyrazolopyrimidine‐ and Pyrazolopyridine‐based B‐RafV600E Kinase Inhibitors by Computational Explorations. (20th March 2014)
- Record Type:
- Journal Article
- Title:
- Insight into the Structural Features of Pyrazolopyrimidine‐ and Pyrazolopyridine‐based B‐RafV600E Kinase Inhibitors by Computational Explorations. (20th March 2014)
- Main Title:
- Insight into the Structural Features of Pyrazolopyrimidine‐ and Pyrazolopyridine‐based B‐RafV600E Kinase Inhibitors by Computational Explorations
- Authors:
- Li, Yan
Han, Chunxiao
Wang, Jinghui
Yang, Yinfeng
Zhang, Jingxiao
Zhang, Shuwei
Yang, Ling - Abstract:
- <abstract abstract-type="main" id="cbdd12276-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Presently, both ligand‐based and receptor‐based 3D‐QSAR modelings were performed on 107 pyrazolopyrimidine‐ and pyrazolopyridine‐based inhibitors of B‐Raf<sup>V600E</sup> kinase. The optimal model is successful to predict the inhibitors' activity with <italic>Q</italic><sup>2</sup> of 0.504, <italic>R</italic><sup>2</sup><sub>ncv</sub> of 0.960, and <italic>R</italic><sup>2</sup><sub>pred</sub> of 0.872. Besides, the 3D contour maps explain well the structural requirements of the interaction between the ligand and the receptor. Furthermore, molecular docking and MD were also carried out to study the binding mode. Our findings are the following: (i) Bulky substituents at position 3, 10 and ring D improve the inhibitory activity, but impair the activity at position 5, 11, and 19. (ii) Electropositive groups at position 10, 13 and 20 and electronegative groups at position 2 increase the biological activity. (iii) Hydrophobic substituents at ring C are beneficial to improve the biological activity, while hydrophilic substituents at position 11 and ring D are good for the activity. (4) This scaffold of inhibitors may bind to the B‐Raf kinase with an 'L' conformation and belong to type III binding mode, which is fixed by hydrophobic interaction and hydrogen bonds with residues from hinge region and DFG motif. These results may be a guidance to develop new<abstract abstract-type="main" id="cbdd12276-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Presently, both ligand‐based and receptor‐based 3D‐QSAR modelings were performed on 107 pyrazolopyrimidine‐ and pyrazolopyridine‐based inhibitors of B‐Raf<sup>V600E</sup> kinase. The optimal model is successful to predict the inhibitors' activity with <italic>Q</italic><sup>2</sup> of 0.504, <italic>R</italic><sup>2</sup><sub>ncv</sub> of 0.960, and <italic>R</italic><sup>2</sup><sub>pred</sub> of 0.872. Besides, the 3D contour maps explain well the structural requirements of the interaction between the ligand and the receptor. Furthermore, molecular docking and MD were also carried out to study the binding mode. Our findings are the following: (i) Bulky substituents at position 3, 10 and ring D improve the inhibitory activity, but impair the activity at position 5, 11, and 19. (ii) Electropositive groups at position 10, 13 and 20 and electronegative groups at position 2 increase the biological activity. (iii) Hydrophobic substituents at ring C are beneficial to improve the biological activity, while hydrophilic substituents at position 11 and ring D are good for the activity. (4) This scaffold of inhibitors may bind to the B‐Raf kinase with an 'L' conformation and belong to type III binding mode, which is fixed by hydrophobic interaction and hydrogen bonds with residues from hinge region and DFG motif. These results may be a guidance to develop new B‐Raf<sup>V600E</sup> kinase inhibitors.</p> </abstract> … (more)
- Is Part Of:
- Chemical biology & drug design. Volume 83:Number 6(2014:Jun.)
- Journal:
- Chemical biology & drug design
- Issue:
- Volume 83:Number 6(2014:Jun.)
- Issue Display:
- Volume 83, Issue 6 (2014)
- Year:
- 2014
- Volume:
- 83
- Issue:
- 6
- Issue Sort Value:
- 2014-0083-0006-0000
- Page Start:
- 643
- Page End:
- 655
- Publication Date:
- 2014-03-20
- Subjects:
- Drugs -- Design -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
615.19005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=01253034-000000000-00000 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1747-0285 ↗
http://www.blackwell-synergy.com/loi/jpp ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cbdd.12276 ↗
- Languages:
- English
- ISSNs:
- 1747-0277
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3139.120000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4322.xml